Clinical Trials
7 trialsNCT05887609 2026-06-04
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
University of Colorado, Denver
Phase 2 Recruiting
NCT07059845 2026-06-04
FLORENZA
AbbVie
Phase 2 Recruiting
NCT05445778 2026-06-02
GLORIOSA
AbbVie
Phase 3 Active not recruiting
NCT03835819 2026-06-01
A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06890338 2026-05-29
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AbbVie
Phase 2 Recruiting
NCT06682988 2026-05-26
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
AbbVie
Phase 2 Recruiting
NCT04274426 2026-05-13
MIROVA
AGO Research GmbH
Phase 2 Active not recruiting